Valuation: Innovent Biologics, Inc.

Capitalization 55.15B 58.81B 7.55B 7.3B 6.89B 6.08B 10.8B 655B 11.99B 81.99B 30.43B 272B 28.28B 27.73B 1,149B P/E ratio 2024 *
-73.5x
P/E ratio 2025 * 269x
Enterprise value 50.17B 53.49B 6.87B 6.64B 6.26B 5.53B 9.82B 596B 10.9B 74.58B 27.67B 248B 25.73B 25.22B 1,045B EV / Sales 2024 *
6.1x
EV / Sales 2025 * 4.68x
Free-Float
93.21%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.24%
1 week+9.62%
Current month+8.62%
1 month+7.00%
3 months-7.59%
6 months-13.81%
Current year-1.91%
More quotes
1 week
32.15
Extreme 32.15
37.45
1 month
28.65
Extreme 28.65
37.45
Current year
28.65
Extreme 28.65
37.75
1 year
28.65
Extreme 28.65
52.15
3 years
18.06
Extreme 18.06
52.15
5 years
18.06
Extreme 18.06
107.10
10 years
14.00
Extreme 14
107.10
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2011-04-27
Director of Finance/CFO 46 2024-02-04
Chief Tech/Sci/R&D Officer - 2020-10-31
Manager TitleAgeSince
Chairman 62 2011-04-27
Director/Board Member 81 2015-10-17
Director/Board Member 66 2018-06-03
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.24%+9.62%-0.28%+5.12% 7.64B
-0.29%-6.21%-11.61%+3.24% 82.2B
+3.89%+17.40%+44.05%+51.29% 55.45B
-0.94%+1.94%+102.18%+116.90% 37.4B
-2.21%-2.07%-42.16%-36.65% 20.77B
-3.57%+7.23%+392.19%+798.22% 14.4B
+0.35%+0.29%+75.29%+146.87% 13.51B
-2.88%-10.05%+15.04%-0.85% 13.16B
+0.08%+1.78%-28.16%-30.63% 12.1B
-1.84%-2.83%+5.42%-42.95% 11.67B
Average -0.85%+1.91%+55.20%+101.06% 26.83B
Weighted average by Cap. +0.03%+1.81%+41.07%+72.15%
See all sector performances

Financials

2024 *2025 *
Net sales 8.23B 8.77B 1.13B 1.09B 1.03B 906M 1.61B 97.68B 1.79B 12.23B 4.54B 40.58B 4.22B 4.14B 171B 10.85B 11.57B 1.48B 1.43B 1.35B 1.2B 2.12B 129B 2.36B 16.13B 5.98B 53.52B 5.56B 5.45B 226B
Net income -766M -817M -105M -101M -95.67M -84.41M -150M -9.1B -167M -1.14B -423M -3.78B -393M -385M -15.97B 161M 171M 21.98M 21.24M 20.06M 17.69M 31.45M 1.91B 34.91M 239M 88.61M 792M 82.37M 80.74M 3.35B
Net Debt -4.99B -5.32B -683M -660M -623M -550M -977M -59.23B -1.08B -7.42B -2.75B -24.61B -2.56B -2.51B -104B -4.43B -4.72B -606M -585M -553M -488M -866M -52.55B -962M -6.58B -2.44B -21.83B -2.27B -2.22B -92.22B
More financial data * Estimated data
Logo Innovent Biologics, Inc.
Innovent Biologics Inc is an investment holding company mainly engaged in the discovery, development, manufacturing, and commercialization of medicines. The Company provides medicines for the treatment of cancer, cardiovascular and metabolism (CVM), autoimmune, eye and other diseases. The Company’s product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), and others.
Employees
5,263
More about the company
Date Price Change Volume
25-02-11 35.00 $ -2.51% 2,775,609
25-02-11 35.90 $ -1.24% 7,660,163
25-02-10 36.35 $ +0.28% 9,516,738
25-02-07 36.25 $ +1.26% 11,951,930
25-02-06 35.80 $ +8.32% 15,947,050

Delayed Quote Hong Kong S.E., February 11, 2025 at 03:08 am EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
AAA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
33.67CNY
Average target price
50.01CNY
Spread / Average Target
+48.52%
Consensus

Quarterly revenue - Rate of surprise